As the six approved CAR-T cell therapies, including Breyanzi®, Abecma™ and CARVYKTI™ are poised to achieve blockbuster status, along with a promising development pipeline, the field of CAR-T cell therapies has gained significant traction

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global CAR-T Cell Therapy Market (4^th Edition), 2022-2035.”

The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:

• A detailed assessment of the current market landscape of CAR-T-cell therapies.
• An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors.
• A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies.
• An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies.
• Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above).
• An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies.
• An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies.
• An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022.
• A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
• An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
• A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies.
• Elaborate profiles of the several leading players in the domain of CAR-T cell therapies.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):

• Target Indication(s)
• Non-Hodgkin’s Lymphoma
• Multiple Myeloma
• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Hodgkin’s Lymphoma
• Acute Myeloid Leukemia
• Ovarian Cancer
• Generalized Myasthenia Gravis (MG)
• Renal Cell Carcinoma

• Target Antigen
• CD19
• BCMA
• CD19/22
• Others

• Key Geographical Regions 
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and North Africa
• Rest of the World 

Transcripts of interviews held with the following senior level representatives of stakeholder companies:

• Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
• Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
• Miguel Forte (Chief Operating Officer, TxCell)
• Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
• Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
• Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
• Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
• Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
• Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), details about CAR-T-cell based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to CAR-T cell immunotherapies and manufacturing capabilities of the players. 

• Autolus
• bluebird Bio
• Bristol Myers Squibb
• Carsgen Therapeutics
• Cellectis
• Cellular Biomedicine Group
• Gilead Sciences
• Innovative Cellular Therapeutics
• Kuur Therapeutics
• Noile-Immune Biotech
• Novartis
• Shanghai GeneChem
• Sinobioway Cell Therapy
• Takara Bio
• Wellington Zhaotai Therapies

Get more details on the CAR-T Cell Therapy Market report https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

You may also be interested in the following titles:

DNA Encoded Libraries

Quantum Computing in Drug Discovery Services Market

You may also like to learn what our experts are sharing in Roots educational series:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com